Cat.No. | Name | Information |
---|---|---|
M1988 | Dabrafenib | Dabrafenib (free base) (GSK2118436A) is a V600 mutant BRAF-specific inhibitor. |
M3026 | Sorafenib (BAY 43-9006) | Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. |
M1774 | PLX-4720 | PLX-4720 is a selective BRAFV600E inhibitor with the IC50 values of 160 nM and 130 nM for B-Raf and BRK respectively. |
M1761 | Vemurafenib (PLX4032) | Vemurafenib (PLX4032) is the first and effective selective inhibitor of B-Raf, which can inhibit RAFV600E and C-RAF-1 activity with IC50 of 31 nM and 48 nM, respectively. Vemurafenib induces autophagy. |
M2319 | AZ628 | AZ628 is a potent inhibitor for wild-type CRAF and BRAF V600E with IC50 of 29 nM and 34 nM, respectively. |
M22476 | Exarafenib | Exarafenib (KIN-2787) is a highly selective, potent, next-generation, pan-RAF inhibitor with activity across BRAF and RAS mutant human tumor cell models. Exarafenib has anticancer activity by suppression of downstream MAPK pathway signaling. |
M21640 | Tinlorafenib | Tinlorafenib (PF-07284890) is an orally active BRAF kinase inhibitor, with IC50 values of 4.25 and 2.7 nM for BRAFV600E/V600K respectively. |
M21520 | Vemurafenib-d5 | Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. |
M21513 | Vemurafenib-d7 | Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. Vemurafenib can induce autophagy. |
M21146 | LUT014 | LUT014, a B-Raf inhibitor with an IC50 value of 11.7 nM, was developed for the study of reducing acne-like lesions associated with EGFR inhibitors at restricted doses. |
M21135 | GNE-9815 | GNE-9815 is one of the most selective kinase inhibitors of RAF, targeting KRAS mutant cancers by combination of drugs. |
M20688 | B-Raf inhibitor 1 (Compound 13) dihydrochloride | B-Raf inhibitor 1 (Compound 13) is a type IIA Raf inhibitor which bind to the DFG-out conformation with ki of 1 nM,1 nM,and 0.3 nM for B-Raf(WT), B-Raf(V600E) and C-Raf, respectively. |
M20678 | Belvarafenib (GDC5573, HM95573, RG6185) | Belvarafenib (GDC5573, HM95573, RG6185) is a selective and orally bioavailable pan-RAF kinase inhibitor with IC50 values of 41 nM, 7 nM and 2 nM for BRAF WT, BRAF(V600E) and CRAF kinases, respectively. |
M20609 | CCT196969 | CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs. |
M20334 | WAY-303292 | WAY-303292 is a inhibitor of B-Raf kinase. |
M20274 | WAY-655860 | WAY-655860 is a inhibitor of B-Raf. |
M20242 | WAY-635114 | WAY-635114 is a inhibitor of B-Raf kinase. |
M20241 | WAY-635109 | WAY-635109 is a inhibitor of B-Raf kinase. |
M20075 | WAY-310819 | WAY-310819 is a B-Raf inhibitor |
M14181 | LY3009120 | LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAFV600E, BRAFWT and CRAFWT with IC50s of 5.8, 9.1 and 15 nM, respectively. |
M10591 | AZ304 | AZ304 is a potent dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF with IC50 values of 79 nM and 38 nM respectively. |
M10475 | Lifirafenib (BGB-283) | Lifirafenib (BGB-283) is a novel potent and selective RAF Kinase and EGFR inhibitor with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant. |
M10438 | BI 882370 | BI 882370 is a highly potent and selective RAF inhibitor that binds to the DFG-out (inactive) conformation of the BRAF kinase. |
M10152 | Naporafenib | Naporafenib (also known as LXH254) is an orally available inhibitor of C-Raf and B-Raf with potential antineoplastic activity. |
M9492 | B-Raf inhibitor 1 | B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 µM and 2 nM for A375 proliferation and A375 p-ERK, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.